Compare SWBI & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | EOLS |
|---|---|---|
| Founded | 1852 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 637.4M | 550.9M |
| IPO Year | 2000 | 2018 |
| Metric | SWBI | EOLS |
|---|---|---|
| Price | $14.19 | $7.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $14.00 | ★ $15.50 |
| AVG Volume (30 Days) | 387.1K | ★ 918.1K |
| Earning Date | 06-17-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 36.67 | 1.23 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $523,845,000.00 | $297,176,000.00 |
| Revenue This Year | $7.61 | $13.27 |
| Revenue Next Year | $3.72 | $17.62 |
| P/E Ratio | $34.51 | ★ N/A |
| Revenue Growth | 10.36 | ★ 11.61 |
| 52 Week Low | $7.87 | $3.86 |
| 52 Week High | $17.56 | $8.43 |
| Indicator | SWBI | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 72.89 |
| Support Level | $13.74 | $6.44 |
| Resistance Level | $14.51 | N/A |
| Average True Range (ATR) | 0.34 | 0.40 |
| MACD | -0.03 | 0.21 |
| Stochastic Oscillator | 11.79 | 92.07 |
Smith & Wesson Brands Inc is a U.S.-based company engaged in manufacturing and selling firearms. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The company sells its products under the Smith and Wesson and Gemtech brands, which are used for defense, law enforcement, hunting, and sporting purposes. Geographically, it sells products globally, with maximum income being generated by the U.S. market from its handgun products.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.